Incyte Corp (INCY) · Oct 29, 2026 · Earnings
Beat — Revenue $1.557B vs ~$1.47B consensus; non-GAAP EPS -$3.60 vs ~$3.93 loss consensus
Incyte earnings beat revenue expectations and raised 2026 guidance, led by Opzelura and hematology/oncology growth while Vega keeps reported profit deeply negative.
Incyte is executing a post-Jakafi diversification strategy, building growth around Opzelura, newer hematology and oncology products, and a late-stage pipeline aimed at extending growth beyond the current franchise.
The quarter beat the operating expectation. Revenue reached $1.557 billion, well above the roughly $1.47 billion published consensus, with non-GAAP diluted EPS of a $3.60 loss also modestly better than the roughly $3.93 loss expected. The headline GAAP loss is much noisier because Vega created a $1.23 billion upfront R&D charge, not because the commercial business deteriorated.
| Figure | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Total revenue (Financial Highlights) | $1.557B (+14%) | $1.366B | ~$1.47B |
| Non-GAAP diluted EPS (Financial Highlights) | $(3.60) | $(2.26) | ~$(3.93) |
| Opzelura sales (Product sales) | $254.9M (+36%) | $188.0M | ~$227.4M |
| Jakafi sales (Product sales) | $826.5M (+4%) | $791.1M | ~$825.7M |
| Hematology and oncology sales (Company commentary) | $235M (+38%) | — | — |
The more important signal is mix, not the one-quarter revenue beat. Jakafi was essentially in line with expectations, but Opzelura materially outperformed and the newer hematology/oncology portfolio grew 38%. The company explicitly framed this as continued core growth beyond Jakafi.
Guidance moved up, but only where execution is strongest. Full-year total net sales guidance rose to $5.21-$5.30 billion from $5.13-$5.26 billion, with the increases concentrated in Opzelura and hematology/oncology; Jakafi and expense guidance were unchanged. That is a cleaner positive signal than the reported EPS, because it says management sees the commercial momentum continuing rather than merely benefiting from a one-off item.
The pipeline story advanced, but remains a future value driver rather than current revenue. Incyte is moving INCA033989 toward another Phase 3 study, keeping late-stage oncology programs active, and targeting several regulatory or clinical milestones through 2027. The discontinuation of the MAESTRA-2 ovarian-cancer study shows the company is pruning weaker positioning while redirecting resources toward first-line maintenance. 〔0〕
Bottom line: This was a narrow earnings beat with a more durable positive underneath: Opzelura and newer oncology products are gaining enough traction to lift guidance, partially validating Incyte’s effort to reduce reliance on Jakafi. The Vega charge obscures near-term GAAP profitability, but it does not change the stronger commercial read-through from the quarter.
TRuE-HS topline data, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!